Holen Sie sich die Stockscreener-App
96.17
2.24%
2.0044
Schlusskurs vom Vortag:
$94.17
Offen:
$93.85
24-Stunden-Volumen:
221.25K
Relative Volume:
0.26
Marktkapitalisierung:
$5.81B
Einnahmen:
$521.31M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-201.16
EPS:
-0.4781
Netto-Cashflow:
$54.87M
1W Leistung:
+9.53%
1M Leistung:
+11.57%
6M Leistung:
+32.75%
1J Leistung:
+129.08%
1-Tages-Spanne:
$93.48
$96.48
1-Wochen-Bereich:
$86.97
$97.51
52-Wochen-Spanne:
$36.88
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
96.23 | 5.68B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum (MIRM) Q1 2025 Earnings Call Transcript - AOL.com
MIRM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MIRM PE Ratio & Valuation, Is MIRM Overvalued - Intellectia AI
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) stock price, news, quote and history - Yahoo Finance UK
Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last? - qz.com
Mirum Pharmaceuticals (MIRM) Rises 5.1%: Can This Upward Momentum Continue? - Bitget
Mirum Pharma (MIRM) Earnings Call Transcript - The Globe and Mail
JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
(MIRM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
US Stocks Recap: Will Mirum Pharmaceuticals Inc stock hit new highs in YEARWeekly Profit Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Does Mirum Pharmaceuticals Inc stock benefit from AI growth2026 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Long Term Share Performance - Yahoo Finance
Hennion & Walsh Asset Management Inc. Sells 17,560 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Tudor Investment Corp ET AL Makes New $2.03 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Stock: Pipeline Progress and Rare Disease Focus for Long-Term Investor Value - AD HOC NEWS
Energy Moves: Will Mirum Pharmaceuticals Inc benefit from AI trendsWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $125.00 - MarketBeat
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report? - finance.yahoo.com
Vanguard disaggregates holdings; Mirum (MIRM) shows 0 shares owned - stocktitan.net
Mirum Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution - 富途牛牛
TD Cowen raises Mirum Pharmaceuticals stock price target to $125 - Investing.com
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Citizens reiterates Mirum Pharmaceuticals stock rating on HDV data By Investing.com - Investing.com Canada
Citizens reiterates Mirum Pharmaceuticals stock rating on HDV data - Investing.com
Investor Mood: What are analysts price targets for Mirum Pharmaceuticals Inc2026 Institutional Moves & High Accuracy Trade Alerts - baoquankhu1.vn
Mirum completes enrollment & screening in liver disease studies - MSN
Citizens reiterates Mirum Pharmaceuticals stock rating ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Mirum Pharmaceuticals stock rating ahead of data - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Receives Buy Rating from HC Wainwright - marketbeat.com
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - MSN
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Stabilizing After Rating Updates? - Kalkine Media
Mirum Pharmaceuticals (MIRM) completes enrollment for phase 3 EXPAND study of LIVMARLI - MSN
Baird updates Mirum Pharmaceuticals (MIRM) valuation following beat-and-raise earnings results - MSN
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
Mirum Pharmaceuticals (MIRM) Completes Enrollment for Phase 3 EXPAND Study of LIVMARLI - Insider Monkey
Responsive Playbooks and the MIRM Inflection - Stock Traders Daily
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
5 Most Promising Stocks Under $100 to Buy - Insider Monkey
RBC Capital initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Why Mirum Pharmaceuticals Stock Is Sinking Today - TipRanks
Penn Capital Management Company LLC Sells 34,265 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 7,287 Shares - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 16,515 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 4,732 Shares - MarketBeat
Mirum Pharma’s chief medical officer Quan sells $670k in stock - Investing.com Canada
Mirum Pharmaceuticals Executives Sell Shares - TradingView
Mirum (NASDAQ: MIRM) CFO exercises performance RSUs, sells shares to cover tax withholding - Stock Titan
Mirum (MIRM) CMO exercises performance RSUs, sells 7,287 shares for tax - Stock Titan
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mirum Pharmaceuticals Inc-Aktie (MIRM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Quan Joanne | CHIEF MEDICAL OFFICER |
Mar 16 '26 |
Sale |
91.98 |
7,287 |
670,243 |
18,864 |
| Ramasastry Saira | Director |
Mar 16 '26 |
Option Exercise |
23.51 |
2,000 |
47,020 |
2,000 |
| Ramasastry Saira | Director |
Mar 16 '26 |
Sale |
90.76 |
2,000 |
181,520 |
0 |
| Radovich Peter | PRESIDENT AND COO |
Mar 16 '26 |
Sale |
91.98 |
16,515 |
1,519,015 |
40,272 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Mar 16 '26 |
Sale |
91.98 |
4,732 |
435,239 |
8,429 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Mar 16 '26 |
Sale |
91.98 |
40,985 |
3,769,714 |
194,309 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):